PTD-DBM

Overview

PTD-DBM is a fusion peptide developed by Professor Kang-Yell Choi's group at Yonsei University in South Korea, combining a protein transduction domain (PTD, an arginine-rich cell-penetrating sequence) with a Dishevelled-binding motif (DBM). The peptide competitively binds the PDZ domain of Dishevelled (Dvl), blocking the interaction between the negative regulator CXXC5 and Dvl, thereby releasing the brake on Wnt/β-catenin signaling. Vialdyne releases PTD-DBM as a lyophilized peptide against a ≥99.0% HPLC main-peak specification, supplied with a batch-specific Certificate of Analysis covering RP-HPLC purity, mass-spec identity, appearance, and water content. Lots are released only after the COA is on file.

Applications & buyer fit

Cosmetic-peptide buyers fall into two groups: established beauty / med-aesthetic brands extending an existing line, and OEM clients building a private-label catalog from scratch. The first group usually wants active material plus stability data in their existing carrier matrix; the second usually wants a finished formulation under their label. Both need INCI naming verified, regulator-specific safety files (CPNP for EU, FDA OTC monograph for US where relevant), and packaging-compatibility data.

Primary buyer fit: academic and contract research laboratories.

Specifications

CAS

1609454-11-6

Molecular Formula

C124H225N61O28S2

Molecular Weight

3082.6 Da

Sequence

H-RRRRRRRR-GGGG-RKTGHQICKFRKC-OH

Appearance

White to off-white lyophilized powder

Purity (HPLC)

≥ 99.0%

Strength

1 mg

Packaging

10 vials/box · base pack (multiples of 10)

MOQ

On request

Lead time

10–18 days

Storage

-20°C, protect from light

Certificate of Analysis

Representative COA previews for PTD-DBM; request the certificate matched to the offered or supplied lot from sales. These are previews — request the full high-resolution certificate for any lot.

VerifiedRequest full COA →

PTD-DBM

VD260428-PTD161 · 99.47%

Regulatory note

Research-use-only reference material; not for human or veterinary use.

Selected literature

1. Lee SH, Seo SH, Lee DH, Pi LQ, Lee WS, Choi KY. Targeting of CXXC5 by a Competing Peptide Stimulates Hair Regrowth and Wound-Induced Hair Neogenesis. J Invest Dermatol. 2017;137(11):2260-2269.
2. Kim D, Garza LA. The Negative Regulator CXXC5: Making WNT Look a Little Less Dishevelled. J Invest Dermatol. 2017;137(11):2248-2250.
3. Ryu YC, Park J, Kim YR, et al. CXXC5 Mediates DHT-Induced Androgenetic Alopecia via PGD2. Cells. 2023;12(4):555.
4. Kim HY, Yoon JY, Yun JH, et al. CXXC5 is a negative-feedback regulator of the Wnt/β-catenin pathway involved in osteoblast differentiation. Cell Death Differ. 2015;22(6):912-920.
5. Ryu YC, Lee DH, Shim J, et al. KY19382, a novel activator of Wnt/β-catenin signalling, promotes hair regrowth and hair follicle neogenesis. Br J Pharmacol. 2021;178(12):2533-2546.
6. Mehta A, Motavaf M, Raza D, McLure AJ, Osei-Opare KD, Bordone LA, Gru AA. Revolutionary Approaches to Hair Regrowth: Follicle Neogenesis, Wnt/β-Catenin Signaling, and Emerging Therapies. Cells. 2025;14(11):779.

Frequently asked questions